ASTRAZEN - Fundamental Analysis: Financial Health & Valuation
← Back to ListKey Parameters
⭐ Fundamental Rating: 3.2
✅ Positive
AstraZeneca has demonstrated strong profit growth in the most recent quarter, driven by approvals for new drugs. The company’s robust ROCE indicates efficient capital utilization and high profitability within its pharmaceutical operations.
⚠️ Limitation
The high P/E ratio suggests potential overvaluation considering current earnings, and the PEG ratio is significantly above 1, implying that the stock's price may not be justified given expected growth. The cyclical nature of the pharmaceutical industry introduces inherent risks regarding future revenues.
📉 Company Negative News
AstraZeneca received CDSCO approval for importing a breast cancer treatment drug and also an approval for a bladder cancer drug, however, this was followed by a 3% jump in shares.
📈 Company Positive News
None found
🏭 Industry
The global pharmaceutical sector is characterized by high R&D investment, patent protection, and stringent regulatory oversight. Despite challenges such as pricing pressures and competition, the industry continues to experience growth driven by an aging population and increasing prevalence of chronic diseases. Innovation and strategic partnerships are key determinants of success in this competitive landscape.
🧾 Conclusion
Given the current undervaluation indicated by a P/E ratio below the sector average and recent approval news, an entry zone between 7,800 ₹ – 8,300 ₹ presents a potentially attractive opportunity. Long-term holding guidance suggests focusing on AstraZeneca's ability to capitalize on its drug approvals and maintain strong margins. The stock represents a moderate investment with potential upside, acknowledging the inherent risks of pharmaceutical innovation.